Mr Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide evidence based medicine function for the ortho-clinical diagnostics unit.
Mr Myslinski was also general manager of Johnson & Johnson’s Veridex, a division focused on molecular diagnostics. Previously, Mr Myslinski held executive roles in venture-backed start-ups, Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer.
Brian Murphy, non-executive chairman of RedPath, said: “Mark is a seasoned executive with considerable experience in developing novel diagnostics for broad market adoption. As we prepare to further penetrate the market for RedPath’s PathFinderTG, a diagnostic platform that resolves diagnostic dilemmas, to a broader audience of clinicians, pathologists, patients and payor organizations, Mark’s track record in these areas clearly made him our top choice.”